AstraZeneca (NASDAQ: AZN) reported Q3 EPS of $2.38, $1.22 better than the analyst estimate of $1.16. Revenue for the quarter came in at $15.19 billion versus the consensus estimate of $14.76 billion.

Guidance
AstraZeneca reiterates its Total Revenue and Core EPS guidance4 for FY 2025 at CER, based on the average foreign exchange rates through 2024.
Total Revenue is expected to increase by a high single-digit percentage
Core EPS is expected to increase by a low double-digit percentage

The Core Tax rate is expected to be between 18-22%

For earnings history and earnings-related data on AstraZeneca (AZN) click here.